ensayo cáncer de pulmon
ensayo cáncer de pulmon

New lung cancer vaccine

Clinical trial for non-small cell lung cancer with resistance to immunotherapy
If you have metastatic non-small cell lung cancer (NSCLC) you may be able to access innovative treatment through our phase III clinical trial

What does the study consist of?

We are evaluating immunotherapy in the form of a vaccine which could become an alternative to chemotherapy in certain lung cancer patients.

Who can participate?

  • Men and women over the age of 18.
  • Those diagnosed with metastatic non-small cell lung cancer.
  • Those who are positive for HLA-A2 (our team will help you to confirm this).

Benefits of participation

  • Access to innovative treatment with specialised medical supervision.
  • Personalised medical attention throughout the trial.
  • Contribution to the advancement of lung cancer research.

Technical information

Trial titleRandomised, open-label phase 3 trial, comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with secondary resistance to Immune Checkpoint Inhibitor (ICI).

Now recruiting

ConditionMetastatic non-small cell lung cancer
PhasePhase III
AgeFrom the age of 18
Protocol codeOSE2101C302 (ARTEMIA)
EudraCT / EUCT number2023-509340-10-00
SponsorOSE Immunotherapeutics
Principal InvestigatorDr. José Manuel Trigo Pérez

Do you think you meet the criteria? Write to us at ensayos.clinicos@hcmarbella.com or call us on +34 626 662 752.

How to participate in the clinical trial

Dr José Manuel Trigo Pérez, principal investigator of the trial
Fill out the formComplete the following form so that our team know you are interested in the clinical trial.
We will contact you personallyOur medical team will contact you to obtain more details and to schedule an appointment.
We will explain everything in detailDuring your appointment we will give you information on the clinical trial, the available treatment options and the next steps, so that you can make an informed decision about your participation.

I would like to participate in the trial

If you would like to know more, call us on +34 626 662 752 or write to us at ensayos.clinicos@hcmarbella.com. We will be happy to help.

    Patient name

    Surname(s)

    Email

    Telephone

    Date of birth

    Language


     
     

    Can you provide us with any medical reports?



     

    All the documents you send us will remain confidential and only be used by our specialists to understand your medical history and to provide you with more personalised care. To enable this, we require you to authorise us this documentation to be sent for data processing.

     

     

     

    Controller: HC Hospitales, S.L. Purpose: To manage appointment request. Duration: The data is deleted as soon as the information is given to you, unless you contact us or ask us to contact you in the future. Recipients: We do not give your data to anyone. Rights: To access, rectify and delete your data, and others explained in additional information https://clientes.prodat.es/privacidad/MLG/HCMARBELLA

     

    Oncology Consultants

    Dr. Cantero González, Alexandra
    Specialist in Medical Oncology
    Clinical Specialism in Lung Cancer and Cancer ImmunotherapySpecialist in Medical Oncology
    Clinical Dedication in Breast and Gynecological Cancer

    Dr. Ponce Aix, Santiago
    Medical Oncology Specialist
    Clinical Dedication in Lung Cancer
    Precision medicine
    Cancer immunotherapy

    Tel.: +34 952 908 628
    +34 609 148 799

    952908898 Oncology
    951829978 Diagnosis by imaging
    951829947 Gynecology
    952908897 Fertility
    951829947 Physiotherapy

     

       

       

      I agree to receive e-mails with offers and news about this and other services. *

      YesNo

       

      Responsible: HC Hospitales, S.L. Purpose: Managing the appointment process. Sending you information by newsletter, upon your acceptance. Duration: The data is deleted once the information has been provided to you, unless you contract our services or request us to contact you in the future. With regard to the newsletter, the data is deleted when you unsubscribe from it. Recipients: We do not disclose your data to any other party. Rights: To access, rectify, and delete your data, as well as further rights explained in the additional information webpage: https://clientes.prodat.es/privacidad/MLG/HCMARBELLA

       

      Patient Services

      • 900877454 Call Center
      • 609 148 799
      • 952908898 Oncology
      • 951829947 Gynecology
      • 952908897 Fertility
      • 952908131 Hospital pharmacy

      Subscribe to our newsletter

      • HC Marbella you can access information relevant and topical written by different professionals of our medical health units.
      Subscribe